The upregulation of heparanase-1 expression has also been documented in hematological malignancies, e.g., for multiple myeloma, in which heparanase-1 represents a prominent biomarker for its early detection and a promising therapeutic target [27,28,29,30,31]. Here, HPSE is linked to AL amyloidosis.